Ana de Carvalho Vaz¹*, João Oliveira², Diana Pinto³, Fernanda Teixeira³, Ana Rita Araújo³ and Laura Marques⁴

¹Department of Pediatrics, Unidade Local de Saúde do Alto Minho, Viana do Castelo, Portugal
²Department of Pediatrics, Centro Materno Infantil do Norte, Centro Hospitalar Universitário do Porto, Porto, Portugal
³Department of Pediatrics, Infectious Diseases and Immunodeficiencies Unit, Centro Materno Infantil do Norte, Centro Hospitalar Universitário do Porto, Porto, Portugal
⁴Department of Pediatrics, Infectious Diseases and Immunodeficiencies Unit, Centro Materno Infantil do Norte, Centro Hospitalar Universitário do Porto, Porto, Portugal

*Corresponding Author:Ana de Carvalho Vaz, Department of Pediatrics, Unidade Local de Saúde do Alto Minho, Viana do Castelo, Portugal.

Received: March 15, 2022; Published: March 25, 2022

Abstract

Poorly controlled moderate-to-severe atopic dermatitis in children and adolescents can result in growth failure, impaired quality of life of patients and their families and a significant increase in healthcare expenses. A 9-year-old boy with severe atopic dermatitis, who was initiated on off-label treatment with dupilumab and presented a significant improvement in dermatitis and quality of life. This case highlights the great potential of dupilumab in the treatment of severe atopic dermatitis in the pediatric population.

Keywords: Dupilumab; Atopic dermatitis; Quality of life; Eczema; Children

References

1. Mortz CG., et al. “Atopic dermatitis from adolescence to adulthood in the TOACS cohort: prevalence, persistence and comorbidities”. Allergy 70 (2015): 836-845.
2. Hanifin JM and Reed ML. Eczema Impact Working Group: “A population-based survey of eczema prevalence in the United States”. Dermatitis 18 (2007): 82-91.
3. Chong JH and Koh MJA. “Non-topical management of recalcitrant pediatric atopic dermatitis”. Archives of Disease in Childhood 102 (2017): 681-686.
4. Slater NA and Morrell DS. “Systemic therapy of childhood atopic dermatitiss”. Clinics in Dermatology 33 (2015): 289-299.
5. Silva D., et al. “Off-label prescribing for allergic diseases in children”. World Allergy Organization Journal 7 (2014): 4.
6. Guttman-Yassky E., et al. “Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis”. The Journal of Allergy and Clinical Immunology 143 (2019): 155-172.
7. Igelman S., et al. “Off-label use of dupilumab for pediatric patients with atopic dermatitis: A multicenter retrospective review”. Journal of the American Academy of Dermatology 82 (2020): 407-411.
8. Simpson EL., et al. “Two phase 3 trials of dupilumab versus placebo in atopic dermatitis”. The New England Journal of Medicine 375 (2016): 2335-2348.
9. Gooderham M., et al. “Dupilumab: A review of its use in the treatment of atopic dermatitis”. The Journal of Allergy and Clinical Immunology 78 (2018): 28.
10. Treister AD and Lio PA. “Long‐term off‐ label dupilumab in pediatric atopic dermatitis: A case series”. Pediatric Dermatology (2018): 1-4.
11.  

Citation

Citation: Ana de Carvalho Vaz., et al. “Dupilumab Successful Treatment of a Child with Severe Atopic Dermatitis”. Acta Scientific Paediatrics 5.4 (2022): 19-23.

Copyright

Copyright: © 2022 Ana de Carvalho Vaz., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.